Health
Results: 1-12 of 8603

United Imaging Unveils Its Full Radiotherapy Portfolio at ESTRO 2026, Highlighting the CE-Marked uRT-linac 506c

Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success

Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet







